Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01590082 · ClinicalTrials.gov registry record · Phase 1
Doxycycline, Temozolomide and Ipilimumab in Melanoma
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Terminated
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT01590082: Clinical Trial Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT01590082 is a Phase 1 study that was terminated before completion, run by M.D. Anderson Cancer Center. The registered enrollment target is 12 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01590082, a Phase 1 study, was terminated before completion, sponsored by M.D. Anderson Cancer Center.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to find the highest tolerable dose of doxycycline that can be combined with temozolomide and ipilimumab in patients with advanced melanoma. The safety and level of effectiveness of the study drug combination will also be studied. Doxycycline is designed to treat bacterial infection. It also blocks a protein called iNOS that is important in tumor cell growth, which may slow the growth of or kill cancer cells. Temozolomide is designed to stop cancer cells from making new DNA (the genetic material of cells). This may stop the cancer cells from dividing into new cells. Ipilimumab is designed to block the activity of cells that decrease the immune system's ability to fight cancer.
Interventions
- DRUG Ipilimumab
- DRUG Temozolomide
- DRUG Doxycycline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2012-11 |
| Est. Completion | 2015-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01590082
The ClinicalTrials.gov registry entry for NCT01590082 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Ipilimumab is the first listed.
NCT01590082 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01590082 about?
NCT01590082 is a clinical study titled "Doxycycline, Temozolomide and Ipilimumab in Melanoma". The goal of this clinical research study is to find the highest tolerable dose of doxycycline that can be combined with temozolomide and ipilimumab in patients with advanced melanoma. The safety and level of effectiveness of the study drug combination will also be studied. Doxycycline is designed t...
What is the current status of trial NCT01590082?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2012-11. Estimated completion is 2015-07.
What interventions are being tested in trial NCT01590082?
The interventions under investigation include: Ipilimumab (DRUG), Temozolomide (DRUG), Doxycycline (DRUG).
Who is sponsoring clinical trial NCT01590082?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.